Organization named in the records

GlaxoSmithKline

Named in 2 passages across 2 documents.

Mentions of GlaxoSmithKline in the public Epstein records, with citations.

Ask the documents about GlaxoSmithKline Search every mention

--}}

Being named in these documents is not an accusation or evidence of wrongdoing. This page reflects only what the public records literally contain, with citations to the original sources.

Where GlaxoSmithKline appears

2 total

Clinical Pharmacology and Principal Investigator on studies of mechanisms of cancer and inflammation at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Medical Oncology fellowship. Jim received hi...

Times Square Tower TEXT-001-HOUSE_OVERSIGHT_024003.txt p.1 View source release ↗

… (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Science and Technology Officer for GlaxoSmithKline (“GSK”). From 1995 to 2001, he led Global Research and Development, Information Technology and Product Strategy an...

James Niedel, MD, Ph.D., (70), Venture Partner, joined Sprout in May 2002 and helped found IMAGES-007-HOUSE_OVERSIGHT_024024.txt p.1 View source release ↗

Also named alongside

New York New Leaf NEW LEAF VENTURES III, L.P Harvard Medical School U.S. Securities and Exchange Commission NEW LEAF VENTURE PARTNERS, L.L.C Boston Consulting Group New Leaf Ventures I, L.P All Sprout Funds U.S. Congress New Leaf Venture Partners Philippe Chambon

Want context across all of these passages at once?

Ask the documents about GlaxoSmithKline